Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 3.100-3.250 for the period, compared to the consensus EPS estimate of 3.130. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ENOV. UBS Group decreased their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Needham & Company LLC decreased their price target on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Wells Fargo & Company decreased their price objective on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis currently has an average rating of “Moderate Buy” and an average price target of $51.00.

Enovis Stock Performance

Shares of ENOV stock opened at $31.53 on Thursday. The stock has a fifty day moving average of $31.43 and a 200 day moving average of $31.53. Enovis has a 52 week low of $25.47 and a 52 week high of $49.83. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -2.21 and a beta of 1.69. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The business had revenue of $383.81 million during the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. As a group, research analysts expect that Enovis will post 2.79 earnings per share for the current year.

Insider Activity

In related news, SVP Bradley J. Tandy purchased 3,200 shares of Enovis stock in a transaction dated Friday, August 22nd. The stock was purchased at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the acquisition, the senior vice president directly owned 43,515 shares of the company’s stock, valued at $1,366,806.15. The trade was a 7.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald acquired 6,457 shares of Enovis stock in a transaction that occurred on Thursday, September 11th. The stock was acquired at an average price of $30.97 per share, with a total value of $199,973.29. Following the completion of the acquisition, the chief executive officer directly owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 12,157 shares of company stock worth $374,760 over the last three months. 2.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming boosted its position in Enovis by 555,600.0% in the second quarter. State of Wyoming now owns 5,557 shares of the company’s stock worth $174,000 after purchasing an additional 5,556 shares during the last quarter. Nomura Holdings Inc. purchased a new position in Enovis in the second quarter worth about $586,000. Public Sector Pension Investment Board boosted its position in Enovis by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 194,703 shares of the company’s stock worth $6,106,000 after purchasing an additional 14,409 shares during the last quarter. FORA Capital LLC purchased a new position in Enovis in the second quarter worth about $304,000. Finally, Tower Research Capital LLC TRC boosted its position in Enovis by 578.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company’s stock worth $136,000 after purchasing an additional 3,706 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.